ASH 2022 Conference Coverage
Playback speed
10 seconds
ASH 2022 The Menin Inhibitor Revumenib (SNDX-5613) Leads to Durable Responses in Pts With KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase 1 Study
By
ASH 2022 Conference Coverage
FEATURING
Ghayas Issa
By
ASH 2022 Conference Coverage
FEATURING
Ghayas Issa
110 views
December 16, 2022
Login to view comments.
Click here to Login
Leukemia